nyuuzyou/wikis huggingface dataset:
Ensartinib (Ensacove)

==General information==
Class/mechanism from the NCI Drug Dictionary: An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, ensartinib binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*ALK+ NSCLC
==History of changes in FDA indication==
*2024-12-18: Approved for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. (Based on eXalt3)
==History of changes in NMPA indication==
*2020-11-17: Initial approval for the second-line treatment of ALK-positive NSCLC after progression or intolerance of crizotinib. (Based on X396-CLI-101)
*2022-03: Approved for the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC). (Based on eXalt3)
==Also known as==
*Code name: X-396
*Brand name: Ensacove
Category:Drugs
Category:Oral medications
Category:ALK inhibitors
Category:ROS1 inhibitors
Category:Non-small cell lung cancer medications
Category:NMPA approved in 2020
Category:FDA approved in 2024
Entinostat (Jingzhuda)

==General information==
Class/mechanism: Histone deacetylase (HDAC) inhibitor. Entinostat inhibits class I histone deacetylases, which regulate gene expression by affecting chromatin structure. HDACs normally catalyze removal of acetyl groups from acetylated lysine residues in histones and non-histone proteins, which helps to regulate gene expression. Inhibition of histone deacetylases results in hyperacetylation of histones and modulates gene expression by creating an open chromatin state that leads to expression of previously silenced genes. Although the mechanism of action is not fully understood, inhibiting HDACs has been observed to result in cell cycle arrest and apoptosis of cancer cells.Entinostat manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
No information available.
==History of changes in NMPA indication==
*2024-04-24: Approved in combination with aromatase inhibitors for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative locally advanced or metastatic breast cancer that has recurred or progressed after endocrine therapy.
==Also known as==
*Code names: MS-275, SNDX-275
*Brand name: Jingzhuda
==References==
Category:Drugs
Category:Oral medications
Category:HDAC inhibitors
Category:Breast cancer medications
Category:NMPA approved in 2024
Entospletinib (GS-9973)

==Mechanism of action==
Spleen tyrosine kinase (SYK) inhibitor
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Chronic lymphocytic leukemia===
# GS-US-339-0102: Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article link to PMC article EuroPMC NCT01799889
==Also known as==
*Code name: GS-9973
Category:Drugs
Category:Oral medications
Category:SYK inhibitors
Category:Chronic lymphocytic leukemia medications (investigational)
Category:Investigational drugs
Envafolimab (Enweida)

==General information==
Class/mechanism: PD-L1 antibody.
Route: SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Toxicity management==
*Immunotherapy toxicity management
==Diseases for which it is used==
*dMMR colorectal cancer
*MSI-H or dMMR solid tumors (tissue-agnostic)
==History of changes in NMPA indication==
*2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options.
*2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced colorectal cancer who have experienced disease progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
==Also known as==
*Code name: KN-035
*Brand name: Enweida
Category:Drugs
Category:Subcutaneous medications
Category:Anti-PD-L1 antibodies
Category:Colorectal cancer medications
Category:Malignant solid neoplasm, MSI-H or dMMR medications
Category:NMPA approved drugs
Eosinophilia

==Definition==
*Mild eosinophilia: Absolute eosinophil count 500 to 1500 cells/μL
*Moderate eosinophilia: Absolute eosinophil count 1500 to 5000 cells/μL
*Severe eosinophilia: Absolute eosinophil count >5000 cells/μL
==Evaluation==
May consist of:
*CBC with differential
*Comprehensive metabolic panel (CMP)
*Peripheral smear
*Vitamin B12 
*Troponin I
*CK
*ANCA
*Strongyloides Antibody
*CHIC2, 4q12 Deletion (FIP1L1 and PDGFRA Fusion) FISH. 
*T-Cell Receptor Gene Rearrangement PCR. 
*Flow cytometry
*BCR-ABL FISH
*Immunoglobulins IgG, IgA, IgM
*Cortisol
*HIV, HTLV-I, HTLV-II serologies
*Serum tryptase
*Stool ova and parasites
*Chest x-ray 
*Echocardiogram
*CT scans to evaluate for pulmonary pathology, lymphadenopathy
*Bone marrow biopsy
*Pulmonary function tests (PFTs)
*Clinical/infection history, international travel
*Medications
Category:Hematology reference pages
Epcoritamab (Epkinly)

==General information==
Class/mechanism from the NCI Drug Dictionary: A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells.
Route: IV
Extravasation: no information
==Diseases for which it is used==
*Diffuse large B-cell lymphoma
*Follicular lymphoma
*High-grade B-cell lymphoma
*Transformed lymphoma
==History of changes in FDA indication==
*2023-05-19: Granted accelerated approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (Based on EPCORE NHL-1)
*2024-06-26: Granted accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma who received at least 2 prior lines of therapy. (Based on EPCORE NHL-1FL)
==History of changes in EMA indication==
*2023-09-25: Granted conditional authorization at Tepkinly. Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
==History of changes in PMDA indication==
*2023-09-25: Newly indicated for the treatment of relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma) or relapsed or refractory follicular lymphoma.
==Also known as==
*Code name: GEN-3013
*Generic name: epcoritamab-bysp
*Brand names: Epkinly, Tepkinly
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-CD20-CD3 bispecific antibodies
Category:Diffuse large B-cell lymphoma medications
Category:Follicular lymphoma medications
Category:High-grade B-cell lymphoma medications
Category:Transformed lymphoma medications
Category:FDA approved in 2023
Category:EMA approved in 2023
Category:PMDA approved in 2023
Epithelioid sarcoma

Back to Top
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
=All lines of therapy=
==Tazemetostat monotherapy==
===Regimen===
FDA-recommended dose
Study 	Dates of enrollment	Evidence
Gounder et al. 2020 (EZH-202)	2015-2017 	Phase 2 (RT)
====Biomarker eligibility criteria====
One or both of the following:
*Loss of INI1 expression by IHC
*Biallelic SMARCB1 alterations
====Targeted therapy====
*Tazemetostat (Tazverik) 800 mg PO twice per day on days 1 to 28
28-day cycles
===References===
# EZH-202: Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT02601950
Category:Epithelioid sarcoma regimens
Category:Disease-specific pages
Category:Soft tissue sarcomas
Category:Pediatric solid tumors
Epoetin alfa-epbx (Retacrit)

==General information==
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors. A biosimilar of epoetin.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Significant side effects==
#Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008 Feb 27;299(8):914-24. link to original article EuroPMC
==History of changes in FDA indication==
* 2018-05-15: FDA approved "for the treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis, use of zidovudine in patients with HIV infection, and the effects of concomitant myelosuppressive chemotherapy. It is also approved for the reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery."
==Also known as==
*Brand name: Retacrit
==References==
Category:Drugs
Category:Intravenous medications
Category:Subcutaneous medications
Category:Hematopoietic growth factors
Category:Erythrocyte growth factors
Category:FDA approved in 2018
Category:Biosimilars
Epoetin alfa (Procrit)

==General information==
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.Epoetin alfa (Procrit) package insert Epoetin alfa (Procrit) package insert (locally hosted backup)Procrit manufacturer's websiteAs of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Significant side effects==
#Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008 Feb 27;299(8):914-24. link to original article EuroPMC
==Diseases for which it is used==
*Myelodysplastic syndrome
==Patient drug information==
*Epoetin alfa (Procrit) patient instructions for useEpoetin alfa (Procrit) patient instructions for use Epoetin alfa (Procrit) patient instructions for use (locally hosted backup)
*Brief patient counseling information can be found in the Epoetin alfa (Procrit) package insert
*Epoetin alfa (Procrit) patient drug information (Chemocare)Epoetin alfa (Procrit) patient drug information (Chemocare)
*Epoetin alfa (Procrit) patient drug information (UpToDate)Epoetin alfa (Procrit) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1989-06-01: Initial FDA approval
==Also known as==
*Generic names: Erythropoetin, Erythropoietin
*Brand names: Ceriton, Dynepo, Epoch, Epofer, Epogen, Epogin, Epoimmun, Epomax, Epopen, Epox, Epoyet, Eprex, Eritrelan, Erypo, Erythrostim, Espo, Globuren, Hemapo, Hemax, LG Espogen, Procrit, Vepox, Vintor, Wepox
==References==
Category:Drugs
Category:Intravenous medications
Category:Subcutaneous medications
Category:Hematopoietic growth factors
Category:Erythrocyte growth factors
Category:Myelodysplastic syndrome medications
Category:FDA approved in 1989
Epoetin beta (Recormon)

Antianemic agent.
==Significant side effects==
#Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008 Feb 27;299(8):914-24. link to original article EuroPMC
==Diseases for which it is used==
*Myelodysplastic syndrome
==Also known as==
*Brand name: Recormon
Category:Drugs
Category:Intravenous medications
Category:Subcutaneous medications
Category:Hematopoietic growth factors
Category:Erythrocyte growth factors
Category:Myelodysplastic syndrome medications
Category:Stub
Epratuzumab (LymphoCide)

==Mechanism of action==
Anti-CD22 antibody
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Acute lymphocytic leukemia===
# SWOG S0910: Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. link to original article link to PMC article EuroPMC NCT00945815
==Also known as==
*Code name: AMG 412, hLL2
*Brand name: LymphoCide
Category:Drugs
Category:Intravenous medications
Category:Anti-CD22 antibodies
Category:Acute lymphoblastic leukemia medications (investigational)
Category:Investigational drugs
Eptifibatide (Integrilin)

==General information==
Class/mechanism: reversibly inhibits the glycoprotein IIb/IIIa receptor on platelets, preventing them from binding to fibrinogen, von Willebrand factor, and other adhesion molecules and thereby inhibiting platelet aggregation.
Route: IV
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Also known as==
*Brand name: Integrilin
Category:Drugs
Category:Intravenous medications
Category:GPIIb-IIIa inhibitors
Category:FDA approved in 1998
Erdafitinib (Balversa)

==General information==
Class/mechanism: Tyrosine kinase inhibitor. Erdafitinib inhibits multiple receptor tyrosine kinases (RTKs), including fibroblast growth factor receptors (FGFR) FGFR1, FGFR2, FGFR3, FGFR4, as well as RET, CSF1R, PDGFRA, PDGFRB, FLT4, KIT, and VEGFR2. Erdafitinib inhibits FGFR-related phosphorylation and signal transduction, resulting in inhibition and tumor cell death in FGFR-overexpressing tumor cells.Erdafitinib (Balversa) package insert Erdafitinib (Balversa) package insert (locally hosted backup)Balversa manufacturer's website
Route: PO
Extravasation: n/a
*Monitor for hyperphosphatemia; dose adjustments may be needed per package insert
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, or the package insert.
==Diseases for which it is established==
*Urothelial carcinoma
==Patient drug information==
*Erdafitinib (Balversa) package insert
==History of changes in FDA indication==
*2019-04-12: Accelerated FDA approval for adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. (Based on BLC2001)
*2023-01-19: Approved for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Based on THOR cohort 1)
==History of changes in Health Canada indication==
*2019-10-25: Initial notice of compliance with conditions for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) whose tumors have susceptible fibroblast growth factor receptor (FGFR)2 or FGFR3 genetic alterations and who have disease progression during or following at least one line of prior chemotherapy, including within 12 months of neoadjuvant or adjuvant chemotherapy.
==Also known as==
*Code name: JNJ-42756493
*Brand name: Balversa
*Synonym: Erda
==References==
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:FGFR inhibitors
Category:Urothelial carcinoma medications
Category:FDA approved in 2019
Category:Health Canada approved in 2019
Erythromycin

An antibiotic.
==Also known as==
*Generic name: ilotycin
*Brand names: Robimycin, E-Mycin, Erymax, Ery-Tab, Eryc, Ranbaxy, Erypar, EryPed, Erythrocot, E-Base, Erythroped, Ilosone, MY-E, Pediamycin, Zineryt, Abboticin, Erycin, Stiemycine, Acnasol, Tiloryth
Category:Drugs
Category:Oral medications
Category:Antibacterials
Category:FDA approved in 1964
Essential thrombocythemia - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main pancreatic cancer page for regimens that include active anticancer treatment.
=First-line therapy=
==Observation==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Cortelazzo et al. 1995	1990-1993 	Phase 3 (C)	Hydroxyurea	Lower thrombotic episode rate
No active antineoplastic treatment; used as a comparator arm.
===References===
# Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
Category:Essential thrombocythemia regimens
Category:Disease-specific pages
Category:Myeloproliferative neoplasms
Category:Null regimens